๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Small Cell Lung Cancer
Clinical trial register · China

Small Cell Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 19 Shanghai 17 Guangzhou 13 Changsha 12 Fuzhou 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd5 Amgen5 Hunan Province Tumor Hospital3 Sichuan Baili Pharmaceutical Co., Ltd.3 MediLink Therapeutics (Suzhou) Co., Ltd.2
Site location
Beijing19 Shanghai17 Guangzhou13 Changsha12 Fuzhou11
All 48 locations
Target enrolment
to

Small Cell Lung Cancer trials in China

61 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
DAREONยฎ-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Nanning, Shanghai
2026-09-29
Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
NCT07778316Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
400
Beijing, Shanghai
2026-08-28
Recruiting
NK Cells Plus ICI for SCLC Maintenance
NCT07759856Small Cell Lung Cancer
Tianjin First Central Hospital
Phase 2
42
Tianjin
2026-08
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai
2026-07-02
Not yet open
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
NCT07559929Small Cell Lung Cancer
DrugsDXC006·Cisplatin·Carboplatin·Tislelizumab
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2
200
Guangzhou
2026-06-01
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
DrugLimertinib
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Recruiting
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
NCT07231445Small Cell Lung Cancer
DrugsZG006·Serplulimab
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
100
Shanghai
2026-04-21
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsHLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Not yet open
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
NCT07398560Small Cell Lung Cancer
DrugAdebrelimab
The Third Affiliated Hospital of Harbin Medical University
Phase 2
47
Harbin
2026-02-01
Recruiting
SKB500 Combinations in Patients With Small Cell Lung Cancer
NCT07296809Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
80
Guangzhou
2026-01-30
Recruiting
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
NCT07189455Small-cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
420
Shanghai
2025-12-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Atezolizumab·Etoposide
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07373964Small Cell Lung Cancer
China Medical University, China
Phase 2
36
Shenyang
2025-10-15
Recruiting
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT07038096Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugsZG005·ZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
350
Guanzhou
2025-09-23
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263Small Cell Lung Cancer
DrugBevacizumab
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Not yet open
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
NCT07004712Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2
46
Beijing
2025-06-01
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
DrugsTam-Peli·Tarlatamab·Durvalumab
Amgen
Phase 1
29
Jinan, Chengdu, Fuzhou
2025-05-16
Not yet open
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
NCT06951841Small Cell Lung Cancer
DrugsAnlotinib·Tislelizumab
China Medical University, China
Phase 4
31
Shenyang
2025-04-30
Recruiting
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
NCT06970795Small Cell Lung Cancer, Other Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
180
Changchuan
2025-04-10
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704Non Small Cell Lung Cancer, Small Cell Lung Cancer
Hunan Cancer Hospital
Phase 3
121
Changsha, Chenzhou, Hengyang, Yueyang
2025-02-25
Recruiting
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
NCT06769971Small Cell Lung Cancer
DrugsCadonilimab·Etoposide·Carboplatin·Bevacizumab
Sichuan University
Phase 2
80
Chengdu
2025-02-01
Recruiting
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
NCT07026669Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
40
Beijing
2025-01-01
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Active, closed
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
NCT06612151Small Cell Lung Cancer
DrugsTopotecan hydrochloride·Tam-Peli
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
438
Guangzhou
2024-12-17
By invitation
INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
NCT06747832Small Cell Lung Cancer
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1
10
Weifang
2024-12-15
Not yet open
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
NCT06724263Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
DrugB1962
Tasly Biopharmaceuticals Co., Ltd.
Phase 2
120
Shanghai
2024-12
Not yet open
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
NCT06497543Small-cell Lung Cancer
DrugPemetrexed
Hunan Province Tumor Hospital
Phase 2
80
Changsha
2024-10-01
Recruiting
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
NCT06873555Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
Heronova Pharmaceuticals
Phase 1/2
60
Bengbu, Changsha
2024-09-11
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
NCT06283719Small Cell Lung Cancer, Neuroendocrine Cancer
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
265
Shanghai
2024-09-02
Recruiting
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
NCT06480864Small Cell Lung Cancer
Yunpeng Liu
Not applicable
38
Shenyang
2024-08-09
Active, closed
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
NCT06500026Small Cell Lung Cancer
DrugsTopotecan·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824Small Cell Lung Cancer, Neuroendocrine Tumors
DrugBL-M14D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Shanghai
2024-08-02
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
DrugsHS-20093·Topotecan
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Recruiting
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
NCT06527898Small-cell Lung Cancer
Anhui Provincial Hospital
Phase 1/2
45
Hefei
2024-07-01
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Lurbinectedin·Ifinatamab Deruxtecan·Topotecan
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
NCT06514118Small-cell Lung Cancer, Residual Tumor, Radiation
Qingdao Central Hospital
Observational
70
Qingdao
2024-04-17
Recruiting
Serplulimab Combined With CCRT for LS-SCLC.
NCT06295926Small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2
96
Beijing
2024-04-04
Recruiting
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
NCT06467786Small Cell Lung Cancer
Tang-Du Hospital
Phase 4
24
Xi'an
2024-03-15
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Recruiting
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT07583511Small-cell Lung Cancer
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
By invitation
Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
NCT06816966Small-cell Lung Cancer
Fujian Medical University Union Hospital
Phase 2
35
Fuzhou
2023-12-26
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
NCT05924841Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
100
Changchun
2023-11-10
Recruiting
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
54
Zhengzhou
2023-10-27
Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06457906Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
340
Beijing
2023-09-01
Active, closed
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
NCT05957510Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
66
Guangzhou
2023-07-07
Recruiting
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
NCT04951947Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2023-06-01
Recruiting
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NCT05552846Small-cell Lung Cancer
Ruijin Hospital
Not applicable
104
Shanghai
2021-01-30
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naรฏve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Recruiting
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
NCT04539977Small-cell Lung Cancer
DrugsEtoposide·Carboplatin
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2020-09-01
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Recruiting
Molecular Analysis and Treatment Options of SCLC
NCT05945745Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage
Shanghai Chest Hospital
Observational
500
Shanghai
2016-01-01
Rows per page Showing 1–61 of 61
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 61 of those studies listing the condition Small Cell Lung Cancer.

How many Small Cell Lung Cancer trials are recruiting in China?

40 of the 61 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 11 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Small Cell Lung Cancer), 61 studies
PhaseStudiesRecruitingShare
Phase 2201232.8%
Phase 315824.6%
Phase 1/211918%
Phase 17511.5%
Observational334.9%
Not applicable223.3%
Phase 4213.3%
Phase EARLY_PHASE1101.6%

Most active sponsors

Lead sponsors with the most studies (Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Amgen51
Suzhou Zelgen Biopharmaceuticals Co.,Ltd55
Hunan Province Tumor Hospital31
Sichuan Baili Pharmaceutical Co., Ltd.32
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
China Medical University, China21
Hangzhou DAC Biotechnology Co., Ltd.21
MediLink Therapeutics (Suzhou) Co., Ltd.21
Merck Sharp & Dohme LLC21
Pfizer21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.